中文摘要：

目的：探讨乳腺癌组织中ER、PR、C-erbB-2、CD44V6和Ki67的表达与年龄、肿瘤大小、临床分期、淋巴结转移的关系以及它们相互之间的线性关系，同时分析其在乳腺癌的发生、发展中所表现出的临床作用和意义。方法：采用免疫组化S—P法检测103例乳腺癌标本中ER、PR、C-erbB-2、CD44V6和Ki67的表达，并与临床病理因素进行相关性分析。结果：103例患者中ER阳性的有57例（55．34％），PR阳性的有49例（47．57％），C-erbB．2阳性的有39例（37．86％），CD44V6阳性的有68例（66．02％），Ki67阳性的有例（90．29％），其中以Ki67的表达率最高，C—erbB．2的表达率最低；不同年龄、淋巴结是否转移对ER、PR、C—erbB-2、CD44V6和Ki67表达量的差异。无统计学意义（P〉0．05）；PR的表达与乳腺癌临床分期相关（P〈0．05），临床分期越高，PR的表达量越低；C．erbB．2的表达与肿瘤大小相关（P〈0．05），肿瘤组织越小，C—erbB-2的表达量越低；ER的表达量和CD44V6的表达量的差异，有统计学意义（P〈0．05）。结论：在乳腺癌发病率越来越高的中国以至世界，免疫组化检测ER、PR、C—erbB-2、CD44V6和Ki67的阴阳性表达，可以作为乳腺癌发生、发展的评价指标，联合检测更加有助于早期乳腺癌患者的临床治疗和预后判断，减轻乳腺癌患者的身体和心理的痛苦，为临床医生选择和评估乳腺癌患者的治疗方案提供一些参考，更为下一步的个体化治疗和基因治疗做了一些前序工作。

英文摘要：

Objective： To investigate the correlations between the age, tumor size, clinical stage and lymph node status of patients with breast cancer and the expressions ofER, PR, C-erbB-2, CD44V6 and 1067 in cancer tissue, and to analysis clinical effect and signif- icance occurring and developing of the breast cancer. Methods： Immunohistochemical method was used to detect the expression of ER, PR, C-erbB-2, CD44V6 and 1067 in 103 breast cancer tissue and correlation with clinicopathological factors analysis. Results： The posi- tivity rate of the expression ofER, PR, C-erbB-2, CD44V6 and 1067 were 55.34 %, 47.57 %, 37.86 %, 66.02 %, 90.29 %, respectively. The highest expression rate was 1067, with C-erbB-2 expression in the lowest rate. There was no significant differences between the age and lymph node status（P〉0.05）. The expression of PR was significant difference in clinical stage （P〈0.05）, The expression of C-erbB-2 was obviously correlated with tumor size （P〈0.05）, The expression of PR was obviously correlated with the expression of CD44V6（P〈0. 05）. Conclusions： The incidence of breast cancer in China and even the world was increasing. Examination of expressions of ER, PR, C-erbB-2, CD44V6 and Ki67 was benefit of therapy and prognosis in primary breast cancer. These could reduce breast cancer＇s physical and mental suffering and provide some reference for clinicians to select and evaluate treatment options for patients with breast cancer, and also did some work for individualized therapy and gene therapy in the next step.